Vera Therapeutics, Inc. VERA 深 滬
等待開盤 10-25 09:30:00 美东时间
29.22
+1.020
+3.62%
華盛通- 最 高29.58
- 今 開28.66
- 成交量 117.47万股
- 最 低 28.24
- 昨 收 28.20
- 總市值 18.65亿
- 52周最高 51.61
- 市盈率 靜 --
- 換手率 1.84%
- 52周最低 18.53
- 委 比 -14.65%
- 總股本 6382.37万
- 歷史最高 51.61
- 量 比 1.16
- 振 幅 4.75%
- 歷史最低 5.20
- 每 手 1
- 風險率 9.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多IBM RELEASES THIRD-QUARTER RESULTS
Acceleration in revenue growth and profit across all segments; Raises outlook for full-year revenue growth and free cash flow ARMONK, N.Y., Oct. 22, 2025 /PRNewswire/ -- IBM (NYSE: IBM) toda...
10-23 04:08
FOX WEATHER TAPS T-MOBILE'S SUPERMOBILE TO POWER EXTREME-WEATHER COVERAGE
T-Mobile's SuperMobile keeps FOX Weather reporters connected with intelligent connectivity, satellite-to-cell coverage and enhanced security — so communities never miss a critical update BE...
10-22 21:52
Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET
Vera Therapeutics will host an investor call on November 6, 2025, to discuss data from the ORIGIN Phase 3 trial of atacicept for IgA nephropathy (IgAN). Jonathan Barratt, MD, PhD, and Richard Lafayette, MD, will join the presentation. Atacicept, a fusion protein targeting BAFF and APRIL, has shown significant reductions in proteinuria and stable kidney function in clinical trials. Vera Therapeutics is advancing atacicept toward potential commerci...
10-22 12:00
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
Vera Therapeutics announced that data from the ORIGIN Phase 3 clinical trial of atacicept for treating IgA nephropathy (IgAN) will be presented at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston. The presentation will highlight the trial's results, with two additional posters detailing the ORIGIN Extend and PIONEER trials. Atacicept, a fusion protein targeting BAFF and APRIL, has shown significant reductions in proteinuria an...
10-17 13:12
美股大行评级 | Needham上调台积电目标价升至360美元！美国银行、摩根士丹利分别获多家机构上调目标价
今日重点评级关注：Rosenblatt：维持HIVE Digital Technologies"买入"评级，目标价从5美元升至10美元；摩根大通：维持Array Technologies"超配"评级，目标价从13美元升至15美元
10-17 09:58
Kodiak's Self-Driving Trucks Achieve Top Score in Nauto Driver Safety Evaluation
Kodiak's autonomous technology ties for the highest safety score among 1,000+ commercial fleets in Nauto's network SUNNYVALE, Calif. and MOUNTAIN VIEW, Calif., Oct. 16, 2025 /PRNewswire/ -- ...
10-16 21:00
B of A Securities Initiates Coverage On Vera Therapeutics with Buy Rating, Announces Price Target of $48
B of A Securities analyst Dina Ramadane initiates coverage on Vera Therapeutics (NASDAQ:VERA) with a Buy rating and announces Price Target of $48.
10-16 19:47
Vera Bradley and the Rockettes Kick Off Special Holiday Partnership
Vera Bradley, Inc. announced a partnership with the Radio City Rockettes to celebrate their respective milestones: the Rockettes’ 100th anniversary and Vera Bradley’s Original 100 Handbag, reintroduced in the 2025 winter collection. The handbag, priced between $75-$135, features six nostalgic patterns and is available nationwide. The collaboration highlights shared values of sisterhood, empowerment, and individuality. The Rockettes will promote t...
10-02 13:55
6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner
Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.
09-30 21:11
Goldman's 48 potential M&A candidates
Deal activity will rise by 15% in 2026, according to Goldman Sachs. Strategist David Kostin says M&A activity will increase next year "alongside accelerating US economic growth, improving CEO confiden...
09-29 03:14
